REFERENCES
1. Bebb R, Millar A, Brock G. Diabetes Canada Clinical Practice Guidelines Expert Committee. Sexual dysfunction and hypogonadism in men with diabetes. Can J Diabetes 2018;42 Suppl 1:S228-33.
2. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care 2018;41:1516-25.
3. Rochira V. Hypogonadism in systemic diseases. In: Simoni M, Huhtaniemi I, editors. Endocrinology of the testis and male reproduction. Cham: Springer International Publishing; 2017. p. 1-51.
4. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288-99.
5. Atlantis E, Fahey P, Martin S, et al. Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocr Disord 2016;16:26.
6. Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15-33.
7. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Available from: https://apps.who.int/iris/bitstream/handle/10665/43588/9241594934_eng.pdf [Last accessed on 29 Nov 2021].
8. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379:2279-90.
9. Alvarez S, Coffey R, Algotar AM. Prediabetes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
10. Sörensen BM, Houben AJ, Berendschot TT, et al. Prediabetes and type 2 diabetes are associated with generalized microvascular dysfunction: the maastricht study. Circulation 2016;134:1339-52.
11. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-7.
12. Corona G, Rastrelli G, Balercia G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 2012;9:1669-80.
13. Buysschaert M, Medina JL, Bergman M, Shah A, Lonier J. Prediabetes and associated disorders. Endocrine 2015;48:371-93.
14. Greco C, Spallone V. Obstructive sleep apnoea syndrome and diabetes. Fortuitous association or interaction? Curr Diabetes Rev 2015;12:129-55.
16. Wu FC, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
18. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715-44.
19. . Swiecicka A, Wu F. Clinical manifestation and diagnosis of androgen deficiency. In: Simoni M, Huhtaniemi I, Editors. Endocrinology of the testis and male reproduction. Cham: Springer International Publishing; 2017. p. 1-18.
20. Dean JD, McMahon CG, Guay AT, et al. The international society for sexual medicine's process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 2015;12:1660-86.
21. Hackett G, Kirby M, Edwards D, et al. British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14:1504-23.
22. Wang C, Nieschlag E, Swerdloff R, et al. International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30:1-9.
23. Salonia A, Bettocchi C, Boeri L, et al. EAU Working Group on Male Sexual and Reproductive Health. European Association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol 2021;80:333-57.
24. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430-9.
25. Huhtaniemi IT, Tajar A, Lee DM, et al. EMAS Group. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol 2012;166:983-91.
26. Frost M, Wraae K, Nielsen TL, et al. Similar reference intervals for total testosterone in healthy young and elderly men: results from the Odense Androgen Study. Clin Endocrinol (Oxf) 2013;78:743-51.
27. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 2012;77:755-63.
28. Grossmann M, Jones TH. Functional hypogonadism in middle-aged and older men: testosterone treatment or not? Eur J Endocrinol 2021;185:D1-9.
29. Gyawali P, Martin SA, Heilbronn LK, et al. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men. Acta Diabetol 2018;55:861-72.
30. Hu J, Zhang A, Yang S, et al. Combined effects of sex hormone-binding globulin and sex hormones on risk of incident type 2 diabetes. J Diabetes 2016;8:508-15.
31. Yao QM, Wang B, An XF, Zhang JA, Ding L. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect 2018;7:220-31.
32. Malipatil NS, Yadegarfar G, Lunt M, et al. Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes. Endocrinol Diabetes Metab 2019;2:e00064.
33. Zhang J, Li X, Cai Z, Li H, Yang B. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male 2020;23:607-18.
34. Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992;35:173-7.
35. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005;90:2636-41.
36. Contreras PH, Serrano FG, Salgado AM, Vigil P. Insulin sensitivity and testicular function in a cohort of adult males suspected of being insulin-resistant. Front Med (Lausanne) 2018;5:190.
37. Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636-42.
38. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834-40.
39. Souteiro P, Belo S, Oliveira SC, et al. AMTCO Group. Insulin resistance and sex hormone-binding globulin are independently correlated with low free testosterone levels in obese males. Andrologia 2018;50:e13035.
40. Arthur R, Rohrmann S, Møller H, et al. Pre-diabetes and serum sex steroid hormones among US men. Andrology 2017;5:49-57.
41. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25:55-60.
42. Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: a narrative review. Diabetes Obes Metab 2021;23:18-28.
43. Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 2016;39:967-81.
44. Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2016;174:R99-116.
45. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-93.
46. Rabijewski M, Papierska L, Piątkiewicz P. The relationships between anabolic hormones and body composition in middle-aged and elderly men with prediabetes: a cross-sectional study. J Diabetes Res 2016;2016:1747261.
47. Caliber M, Saad F. Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone. Curr Opin Pharmacol 2021;58:83-9.
48. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol 2021;9:32-45.
49. Haider KS, Haider A, Saad F, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab 2020;22:2055-68.
50. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995;80:239-43.
51. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006;147:141-54.
52. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003;144:5081-8.
53. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab 2010;12:941-6.
54. Benvenuti S, Cellai I, Luciani P, et al. Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells. J Endocrinol Invest 2012;35:365-71.
55. Abdelzaher WY, Rofaeil RR, Ali DME, Attya ME. Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1α and nitric oxide. Naunyn Schmiedebergs Arch Pharmacol 2020;393:603-14.
56. Rabijewski M, Papierska L, Piątkiewicz P. Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population. Aging Male 2015;18:16-21.
57. Boeri L, Capogrosso P, Pederzoli F, et al. Unrecognized prediabetes is highly prevalent in men with erectile dysfunction-results from a cross-sectional study. J Sex Med 2018;15:1117-24.
58. Boeri L, Capogrosso P, Ventimiglia E, et al. Undiagnosed prediabetes is highly prevalent in primary infertile men - results from a cross-sectional study. BJU Int 2019;123:1070-7.
59. Ho CH, Yu HJ, Wang CY, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One 2013;8:e74173.
60. Zhu H, Wang N, Han B, et al. Low Sex Hormone-binding globulin levels associate with prediabetes in chinese men independent of total testosterone. PLoS One 2016;11:e0162004.
61. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23:912-8.
62. Lu Y, Li J, Cheng X, et al. Testosterone level in aging male with different glucose tolerance state and its association with osteocalcin. Aging Male 2019;22:68-73.
63. Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care 2009;32:1049-51.
64. Liu X, Jiang J, Liu X, et al. Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the henan rural cohort study. Diabetes Metab Res Rev 2019;35:e3133.
65. Chen X, Wu Y, Liu L, Tian H, Yu X. Osteocalcin is inversely associated with glucose levels in middle-aged Tibetan men with different degrees of glucose tolerance. Diabetes Metab Res Rev 2014;30:476-82.
66. Minooee S, Ramezani Tehrani F, Rahmati M, et al. The association between serum total testosterone and progression of hyperglycemia: a 15-year prospective cohort study. Andrology 2019;7:148-55.
67. Rabijewski M, Papierska L, Piątkiewicz P. The prevalence of prediabetes in population of Polish men with late-onset hypogonadism. Aging Male 2014;17:141-6.
68. Krysiak R, Gilowski W, Okopien B. The effect of metformin and metformin-testosterone combination on cardiometabolic risk factors in men with late-onset hypogonadism and impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2015;123:608-13.
69. Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care 2019;42:1104-11.
70. Strollo F, Strollo G, Morè M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male 2013;16:33-7.
71. Krysiak R, Szkróbka W, Bednarska-Czerwińska A, Okopień B. Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. Fundam Clin Pharmacol 2021;35:466-72.
72. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490-4.
73. Ottarsdottir K, Nilsson AG, Hellgren M, Lindblad U, Daka B. The association between serum testosterone and insulin resistance: a longitudinal study. Endocr Connect 2018;7:1491-500.
74. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010;7:1627-56.
75. Boeri L, Capogrosso P, Ventimiglia E, et al. Sexual dysfunction in men with prediabetes. Sex Med Rev 2020;8:622-34.
76. Rastrelli G, O'Neill TW, Ahern T, et al. EMAS study group. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: prospective results from the EMAS. Clin Endocrinol (Oxf) 2018;89:459-69.
77. Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-88.
78. Ballester J, Muñoz MC, Domínguez J, Rigau T, Guinovart JJ, Rodríguez-Gil JE. Insulin-dependent diabetes affects testicular function by FSH- and LH-linked mechanisms. J Androl 2004;25:706-19.
79. Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007;4:620-32.
80. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-5.
81. Khaw K, Barrett-connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992;2:675-82.
82. Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101-4.
83. Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-51.
84. Mårin P, Holmäng S, Jönsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16:991-7.
85. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-8.
86. Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 2016;39:82-91.
87. Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia 2021; doi: 10.1007/s00125-021-05592-3.
88. Giagulli VA, Castellana M, Carbone MD, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology 2020;8:654-62.
89. Ognjenovic M, Ambrosini GL, Malacova E, et al. Associations between major dietary patterns and testicular function in a population-based cohort of young men: results from the Western Australian Pregnancy Cohort (Raine) Study. Andrology 2019;7:273-80.
90. Grossmann M, Fui MNT, Nie T, et al. Changes in white adipose tissue gene expression in a randomized control trial of dieting obese men with lowered serum testosterone alone or in combination with testosterone treatment. Endocrine 2021;73:463-71.
91. Steeves JA, Fitzhugh EC, Bradwin G, McGlynn KA, Platz EA, Joshu CE. Cross-sectional association between physical activity and serum testosterone levels in US men: results from NHANES 1999-2004. Andrology 2016;4:465-72.
92. Kanakis GA, Tsametis CP, Goulis DG. Measuring testosterone in women and men. Maturitas 2019;125:41-4.
93. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 2010;121:496-504.
